Skip to content
ChickenStockChickenStock
ResearchMAZE
Maze Therapeutics logo

Maze Therapeutics (MAZE) stock

NASDAQ

$34.32-4.90%(-1.77)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 13, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

-12.50x

Net loss — not comparable

P/B

4.40x

P/S

11.24x

Latest earnings

SEC filings

Jul–Sep 2026(FY2026 Q3)

Operating income decreased from the same period a year earlier.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 9, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

40 SEC filings
  • Coloma Jason VChief Executive Officer · Nov 2, 2026Open-market sale34,501 shares · $1.0M
    Avg. price $30.2532
    Show 4 price lots
    • 26,563 shares × $30.095$799K
    • 5,345 shares × $31.0528$166K
    • 2,257 shares × $30.1241$68K
    • 336 shares × $30.9089$10K
  • Dandekar AtulCSBO · Oct 29, 2026Open-market sale7,500 shares · $241K
    Avg. price $32.070932,316 shares held after
  • Dandekar AtulCSBO · Oct 29, 2026Option exercise7,500 shares · $78K
    Avg. price $10.42
    Show 2 price lots
    • 6,643 shares × $10.42$69K
    • 857 shares × $10.42$9K
  • Coloma Jason VChief Executive Officer · Oct 1, 2026Open-market sale34,501 shares · $932K
    Avg. price $27.0212
    Show 2 price lots
    • 31,908 shares × $27.021$862K
    • 2,593 shares × $27.0241$70K
  • Bernstein HaroldPresident, R&D & CMO · Oct 1, 2026Open-market sale16,141 shares · $435K
    Avg. price $26.93410 shares held after
  • Bernstein HaroldPresident, R&D & CMO · Oct 1, 2026Option exercise16,141 shares · $168K
    Avg. price $10.4216,141 shares held after
  • Dandekar AtulCSBO · Sep 29, 2026Open-market sale7,500 shares · $203K
    Avg. price $27.056132,316 shares held after
  • Dandekar AtulCSBO · Sep 29, 2026Option exercise7,500 shares · $78K
    Avg. price $10.4239,816 shares held after
  • Bernstein HaroldPresident, R&D & CMO · Sep 4, 2026Open-market sale9,705 shares · $255K
    Avg. price $26.22380 shares held after
  • Coloma Jason VChief Executive Officer · Sep 3, 2026Open-market sale11,411 shares · $297K
    Avg. price $26.0106
    Show 2 price lots
    • 11,282 shares × $26.0133$293K
    • 129 shares × $25.7749$3K
  • Bernstein HaroldPresident, R&D & CMO · Sep 3, 2026Open-market sale5,189 shares · $135K
    Avg. price $26.0106
    Show 2 price lots
    • 5,130 shares × $26.0133$133K
    • 59 shares × $25.78$2K
  • Dandekar AtulCSBO · Sep 3, 2026Open-market sale3,243 shares · $84K
    Avg. price $26.011
    Show 2 price lots
    • 3,207 shares × $26.0133$83K
    • 36 shares × $25.81$929
  • Courtney PhillipsGC and Corp. Secretary · Sep 3, 2026Open-market sale2,012 shares · $52K
    Avg. price $26.0108
    Show 2 price lots
    • 1,990 shares × $26.0133$52K
    • 22 shares × $25.78$567
  • Coloma Jason VChief Executive Officer · Sep 2, 2026Open-market sale11,227 shares · $297K
    Avg. price $26.4673
    Show 2 price lots
    • 9,852 shares × $26.376$260K
    • 1,375 shares × $27.1211$37K
  • Bernstein HaroldPresident, R&D & CMO · Sep 2, 2026Open-market sale5,106 shares · $135K
    Avg. price $26.4672
    Show 2 price lots
    • 4,481 shares × $26.376$118K
    • 625 shares × $27.1211$17K
  • Dandekar AtulCSBO · Sep 2, 2026Open-market sale3,191 shares · $84K
    Avg. price $26.4673
    Show 2 price lots
    • 2,800 shares × $26.376$74K
    • 391 shares × $27.1211$11K
  • Courtney PhillipsGC and Corp. Secretary · Sep 2, 2026Open-market sale1,981 shares · $52K
    Avg. price $26.4674
    Show 2 price lots
    • 1,738 shares × $26.376$46K
    • 243 shares × $27.1211$7K
  • Coloma Jason VChief Executive Officer · Sep 1, 2026Open-market sale34,501 shares · $907K
    Avg. price $26.2891
    Show 2 price lots
    • 31,908 shares × $26.2876$839K
    • 2,593 shares × $26.307$68K
  • Bernstein HaroldPresident, R&D & CMO · Sep 1, 2026Open-market sale16,141 shares · $426K
    Avg. price $26.36220 shares held after
  • Bernstein HaroldPresident, R&D & CMO · Sep 1, 2026Option exercise36,141 shares · $168K
    Avg. price $4.6537
    Show 2 price lots
    • 16,141 shares × $10.42$168K
    • 20,000 shares × $0$0
  • Dandekar AtulCSBO · Sep 1, 2026Option exercise12,500 shares · $0
    Avg. price $038,750 shares held after
  • Courtney PhillipsGC and Corp. Secretary · Sep 1, 2026Option exercise11,000 shares · $0
    Avg. price $011,000 shares held after
  • Coloma Jason VChief Executive Officer · Sep 1, 2026Option exercise50,000 shares · $0
    Avg. price $050,000 shares held after
  • Dandekar AtulCSBO · Aug 28, 2026Open-market sale7,500 shares · $207K
    Avg. price $27.576526,250 shares held after
  • Dandekar AtulCSBO · Aug 28, 2026Option exercise7,500 shares · $78K
    Avg. price $10.4233,750 shares held after

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

40 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Maze Therapeutics (MAZE) stock information

NASDAQ

Maze Therapeutics (MAZE) is listed on NASDAQ. Its market capitalization is about $1.9B. On trailing-twelve-month earnings the P/E ratio is -12.5, and the P/B ratio is 4.4. Return on equity is -35.2%. These figures are computed in-house from official filings and are reference information only.

Maze Therapeutics — frequently asked questions

What is the P/E ratio of Maze Therapeutics (MAZE)?
On a trailing-twelve-month basis, MAZE trades at a P/E ratio of -12.5. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Maze Therapeutics?
MAZE has a market capitalization of about $1.9B. The figure moves with the share price and is refreshed each trading day.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.